Answers are grounded in this paper and cite their sources.
Meta-analysis finds luspatercept significantly reduces transfusion needs in β-thalassemia, indicating strong efficacy and safety.
Background: Luspatercept is a first-in-class erythroid maturation agent approved for adult transfusion-dependent β-thalassemia. Phase III trials demonstrated significant reductions in transfusion requirements via TGF-β superfamily ligand binding and SMAD2/3 attenuation. We conducted a meta-analysis to quantify efficacy and safety across transfusion-dependent (TDT) and non-transfusion-dependent (NTDT) populations. Methods: PubMed, Embase, and Google Scholar were searched through July 2025 for prospective luspatercept trials in β-thalassemia, excluding duplicate extensions. Four studies (n=393) met inclusion: two randomized trials (BELIEVE in TDT and BEYOND in NTDT) and two phase II single-arm trials. Pooled proportions for ≥33% and ≥50% transfusion reduction (TDT) and ≥1.0 and ≥1.5 g/dL hemoglobin increase (NTDT), along with safety data on any grade ≥3 treatment-emergent adverse events and 95% confidence intervals, were estimated using a random-effects model (DerSimonian-Laird). Heterogeneity was assessed by I², publication bias by funnel plot symmetry, and sensitivity analyses excluded single-arm trials. Risk of bias (Cochrane) and evidence quality (GRADE) were evaluated. Results: In transfusion-dependent β-thalassemia (TDT), the pooled proportion achieving ≥33% reduction in transfusion burden was 74% (95% CI 65–82%; I²=48%), and 27% (95% CI 20–35%; I²=35%) achieved ≥50% reduction. These results align with the BELIEVE trial, in which 70.5% vs 29.5% of patients achieved ≥33% reduction with luspatercept vs placebo. In BELIEVE, the odds of ≥33% reduction with luspatercept were 5.8 (95% CI 4.1-7.8), nearly sixfold that with placebo. In non–transfusion-dependent β-thalassemia (NTDT), pooled response rates were 78% (95% CI 69–85%; I²=22%) for achieving ≥1.0 g/dL hemoglobin increase and 54% (95% CI 44–64%; I²=30%) for achieving ≥1.5 g/dL increase. This is consistent with BEYOND trial findings: 77.1% of luspatercept-treated NTDT patients achieved a ≥1.0 g/dL Hb increase (vs. 0% with a placebo), and >50% achieved a ≥1.5 g/dL increase. Overall, any TEAE occurred in 98% of patients (95% CI 96–99%; I²=12%), and grade ≥3 AEs occurred in 24% (95% CI 18–31%; I²=18%). Luspatercept was generally well tolerated, with predominantly musculoskeletal pain, headache, and arthralgia. No new safety signals were identified. Conclusions: Luspatercept demonstrates substantial and consistent benefit in β-thalassemia: in TDT it markedly reduces transfusion burden, and in NTDT it significantly increases hemoglobin, with an acceptable safety profile. Despite limited trial numbers and heterogeneity, these findings support luspatercept as a transformative therapy in β-thalassemia, though evidence certainty is limited by the available data. The key limitations included a small number of studies, which introduced a single data theory' and limited generalizability, as well as heterogeneity in study design, endpoints, and follow-up durations. Only BELIEVE was placebo-controlled; the others were single-arm, and several endpoints lacked uniform reporting. Risk-of-bias was moderate overall, and the GRADE assessment noted imprecision and inconsistency affecting evidence certainty. Further large trials with standardized endpoints are warranted.
No takes yet. Share an insight, caveat, or question.
Nimmagadda et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: